Cytokine News and Research

RSS

Studies identify protein that drives inflammation in pancreatic, breast tumors

Separate studies published online on February 21 in the Journal of Experimental Medicine (www.jem.org) identify a protein that drives tumor-promoting inflammation in pancreatic and breast tumors.

21 Feb 2011

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 – 19, 2011.

19 Feb 2011

Study confirms anti-inflammatory properties of Oligonol in humans

A recently published study in Nutrition Research and Practice has verified the anti-inflammatory effects in humans of Oligonol® lychee fruit polyphenol. The study examined Oligonol intake on cortisol and related cytokines in healthy young men. Both cortisol and cytokine concentrations are inflammatory markers known to increase when stress such as exercise is caused on the body.

15 Feb 2011

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

14 Feb 2011

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries.

14 Feb 2011

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

11 Feb 2011

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.

9 Feb 2011

bcl3 gene limits lung injury during acute stress from illness, trauma, transplant

Lung injury is a common cause of death among patients with pneumonia, sepsis or trauma and in those who have had lung transplants. The damage often occurs suddenly and can cause life-threatening breathing problems and rapid lung failure.

9 Feb 2011

Cell signaling hormone boosts immune response to clear HIV-like infection

Australian scientists have successfully cleared a HIV-like infection from mice by boosting the function of cells vital to the immune response.

4 Feb 2011

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer.

2 Feb 2011

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting chronic brain inflammation years after stroke are reported.

2 Feb 2011

Scientist identifies natural signaling molecule that can prevent Hemophilia A

A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.

1 Feb 2011

Histamine can be an important molecule to develop new treatments for MS

If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.

1 Feb 2011

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

A drug called etanercept can restore responsiveness to the pain-relieving effects of morphine in rats that have developed morphine tolerance, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Jan 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

New research says EPO hormone can modulate immune response

New research reveals that a hormone best known for stimulating the production of red blood cells can modulate the immune response. The study, published by Cell Press in the January 27th issue of the journal Immunity, finds that erythropoietin has contrasting influences on infectious and inflammatory diseases and may be useful in the design of new therapeutic strategies.

21 Jan 2011

Cytokine News and Research

Studies identify protein that drives inflammation in pancreatic, breast tumors

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Study confirms anti-inflammatory properties of Oligonol in humans

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

bcl3 gene limits lung injury during acute stress from illness, trauma, transplant

Cell signaling hormone boosts immune response to clear HIV-like infection

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

Scientist identifies natural signaling molecule that can prevent Hemophilia A

Histamine can be an important molecule to develop new treatments for MS

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

New research says EPO hormone can modulate immune response

Endothelial cells may play a role in controlling cancer behavior: New study

Positive preliminary results from Soligenix's SGX202 in GARS model

Scientists identify new way of attacking breast cancer stem cells

T.A. Sciences receives US patent for TA-65 to tackle aging process

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News